Tissue Repair
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 2 Dec 2025
- Reported shorts
- 7.7K
- Shares on issue
- 60.465M
Tissue Repair (TRP) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $559.7Kvs n/a (FY25)
- Yahoo Finance, as at 14 Oct 2026
- NPAT
- −$5.4Mvs n/a (FY25)
- Yahoo Finance, as at 14 Oct 2026
- EPS (diluted)
- −$0.089T (source: Derived: trailing 12 months at year end)vs −$0.070 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Summary of Appendix 4E and Annual Report 30 June 2026, 31 Aug 2026
Tissue Repair Ltd reported revenue of $3.21 million for the year ended 30 June 2026, down 0.4%, and a net loss of $5.36 million, which widened by 26.5% from the prior year. No dividends were paid or declared. The company is evaluating a medical device approval pathway for its wound healing product, which could open new market opportunities.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 14 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- −1,425.0%
- Net margin
- −958.0%
- FCF margin
- −1,348.5%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 6.4×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $5.1M
- P/E
- n/a
- P/B
- 0.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $559.7K | n/a | $152.2K | $3.1K |
| Gross profit | $559.7K | n/a | $152.2K | $3.1K |
| Operating income | −$8.0M | n/a | −$6.5M | −$5.7M |
| EBITDA | −$7.8M | n/a | −$6.5M | −$5.7M |
| EBIT | −$8.0M | n/a | −$6.5M | −$5.7M |
| Pretax income | −$5.4M | n/a | −$4.1M | −$4.2M |
| Tax | $0 | n/a | $0 | $0 |
| NPAT | −$5.4M | n/a | −$4.1M | −$4.2M |
| Net interest income | $214.9K | n/a | $743.4K | $430.2K |
| EPS basic | −$0.089T (source: Derived: trailing 12 months at year end) | −$0.070 | −$0.068 | −$0.069 |
| EPS diluted | −$0.089T (source: Derived: trailing 12 months at year end) | −$0.070 | −$0.068 | −$0.069 |
| Shares | 60.5M | n/a | 60.5M | 60.5M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual Report 30 June 2026Annual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D and Half Year Report to 31 December 2025Half Year Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Oct 2025via asx_announcements
- Appendix 4E and Annual Report 30 June 2025Annual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Appendix 4D and Half Year Report to 31 December 2024Half Year Results27 Feb 2025via asx_announcements
Showing 10 of 19 reports